KR20200035973A - 비대성 심근병증의 치료에서 사용하기 위한 마바캄텐 - Google Patents

비대성 심근병증의 치료에서 사용하기 위한 마바캄텐 Download PDF

Info

Publication number
KR20200035973A
KR20200035973A KR1020207004507A KR20207004507A KR20200035973A KR 20200035973 A KR20200035973 A KR 20200035973A KR 1020207004507 A KR1020207004507 A KR 1020207004507A KR 20207004507 A KR20207004507 A KR 20207004507A KR 20200035973 A KR20200035973 A KR 20200035973A
Authority
KR
South Korea
Prior art keywords
compound
subject
daily dose
plasma concentration
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207004507A
Other languages
English (en)
Korean (ko)
Inventor
마크 제이. 세미그란
준 에이치. 리
조셉 램빙
에릭 그린
마크 에반칙
Original Assignee
미요카디아, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미요카디아, 인크. filed Critical 미요카디아, 인크.
Priority to KR1020257024814A priority Critical patent/KR20250116181A/ko
Publication of KR20200035973A publication Critical patent/KR20200035973A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
KR1020207004507A 2017-08-04 2018-08-03 비대성 심근병증의 치료에서 사용하기 위한 마바캄텐 Ceased KR20200035973A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257024814A KR20250116181A (ko) 2017-08-04 2018-08-03 비대성 심근병증의 치료에서 사용하기 위한 마바캄텐

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762541591P 2017-08-04 2017-08-04
US62/541,591 2017-08-04
US201762584537P 2017-11-10 2017-11-10
US62/584,537 2017-11-10
US201862639922P 2018-03-07 2018-03-07
US62/639,922 2018-03-07
US201862671585P 2018-05-15 2018-05-15
US62/671,585 2018-05-15
PCT/US2018/045180 WO2019028360A1 (en) 2017-08-04 2018-08-03 MAVACAMTEN FOR USE IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257024814A Division KR20250116181A (ko) 2017-08-04 2018-08-03 비대성 심근병증의 치료에서 사용하기 위한 마바캄텐

Publications (1)

Publication Number Publication Date
KR20200035973A true KR20200035973A (ko) 2020-04-06

Family

ID=63350605

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207004507A Ceased KR20200035973A (ko) 2017-08-04 2018-08-03 비대성 심근병증의 치료에서 사용하기 위한 마바캄텐
KR1020257024814A Pending KR20250116181A (ko) 2017-08-04 2018-08-03 비대성 심근병증의 치료에서 사용하기 위한 마바캄텐

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257024814A Pending KR20250116181A (ko) 2017-08-04 2018-08-03 비대성 심근병증의 치료에서 사용하기 위한 마바캄텐

Country Status (17)

Country Link
US (5) US20200054636A1 (enExample)
EP (2) EP3661514B1 (enExample)
JP (3) JP2020529996A (enExample)
KR (2) KR20200035973A (enExample)
CN (2) CN118593507A (enExample)
AU (2) AU2018311974B2 (enExample)
CA (1) CA3071948A1 (enExample)
IL (2) IL322175A (enExample)
LT (1) LT3661514T (enExample)
MA (1) MA49760A (enExample)
MX (3) MX2020001406A (enExample)
MY (1) MY208231A (enExample)
RU (1) RU2020109345A (enExample)
SG (2) SG11202000549TA (enExample)
SM (1) SMT202500413T1 (enExample)
UY (1) UY37834A (enExample)
WO (1) WO2019028360A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3740481B9 (en) 2018-01-19 2024-10-23 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
EP3814342B1 (en) 2018-06-26 2022-07-27 Cytokinetics, Inc. Cardiac sarcomere inhibitors
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
WO2020257609A1 (en) * 2019-06-21 2020-12-24 MyoKardia, Inc. Diagnostics and treatments for cardiac disease
CN110698415B (zh) * 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途
US20230158027A1 (en) * 2019-11-10 2023-05-25 MyoKardia, Inc. Methods of treatment with myosin modulator
WO2021154904A1 (en) * 2020-01-28 2021-08-05 Teva Pharmaceuticals International Gmbh Solid state forms of mavacamten and process for preparation thereof
EP4203927A4 (en) * 2020-08-28 2024-09-04 MyoKardia, Inc. METHODS OF TREATMENT BY MYOSIN MODULATOR
WO2022105852A1 (zh) 2020-11-20 2022-05-27 江苏恒瑞医药股份有限公司 三嗪二酮类衍生物、其制备方法及其在医药上的应用
CA3206864A1 (en) * 2021-02-01 2022-08-04 Divya Jyothi Kallem Process for preparation of mavacamten and solid state forms thereof
MX2023010125A (es) 2021-03-04 2023-09-11 Cytokinetics Inc Inhibidores del sarcomero cardiaco.
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法
WO2022189599A1 (en) 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
RS66640B1 (sr) * 2021-07-16 2025-04-30 Cytokinetics Inc Režimi doziranja aficamtena za lečenje opstruktivne hipertrofične kardiomiopatije
WO2023046413A1 (en) * 2021-09-24 2023-03-30 Koninklijke Philips N.V. Methods and systems for generating likelihood of heart failure with preserved ejection fraction (hfpef)
WO2024097284A1 (en) * 2022-11-02 2024-05-10 MyoKardia, Inc. Mavacamten and derivatives thereof for use in treating atrial dysfunction
AU2024248193A1 (en) 2023-03-27 2025-10-09 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache

Also Published As

Publication number Publication date
MX2024000348A (es) 2024-01-26
MX2020001406A (es) 2020-03-09
CN111182901A (zh) 2020-05-19
KR20250116181A (ko) 2025-07-31
JP2020529996A (ja) 2020-10-15
IL272300B1 (en) 2025-08-01
US20250213565A1 (en) 2025-07-03
AU2024203872A1 (en) 2024-06-27
UY37834A (es) 2019-02-28
EP3661514B1 (en) 2025-09-17
IL322175A (en) 2025-09-01
EP3661514A1 (en) 2020-06-10
US20240423981A1 (en) 2024-12-26
JP2025020292A (ja) 2025-02-12
EP4659806A2 (en) 2025-12-10
RU2020109345A (ru) 2021-09-06
MX2024008096A (es) 2024-07-15
CN118593507A (zh) 2024-09-06
CA3071948A1 (en) 2019-02-07
IL272300A (en) 2020-03-31
AU2018311974B2 (en) 2024-03-07
TW201916882A (zh) 2019-05-01
IL272300B2 (en) 2025-12-01
MY208231A (en) 2025-04-25
SMT202500413T1 (it) 2025-11-10
AU2018311974A1 (en) 2020-02-06
US20200054636A1 (en) 2020-02-20
US20220313695A1 (en) 2022-10-06
WO2019028360A1 (en) 2019-02-07
SG10202112960QA (en) 2021-12-30
US20220226324A1 (en) 2022-07-21
LT3661514T (lt) 2025-11-10
SG11202000549TA (en) 2020-02-27
MA49760A (fr) 2020-06-10
JP2023065372A (ja) 2023-05-12

Similar Documents

Publication Publication Date Title
US20250213565A1 (en) Treatment of hcm with pyrimidinedione compounds
CN112912071A (zh) 降低接受他汀类药物治疗的受试者对外周动脉血运重建的需求的方法
CN102065855A (zh) 决奈达隆在制备用于预防因心血管疾病住院或死亡的药物中的用途
CN116490185A (zh) 用肌球蛋白调节剂治疗的方法
TW202320763A (zh) 治療肥厚性心肌病之方法
UA100119C2 (uk) Застосування 3-альфа-андростандіолу в поєднанні з агоністом 5-ht1а для лікування сексуальної дисфункції
KR20250050043A (ko) 비폐쇄성 비대심근병증 치료 방법
JP2019517459A (ja) 心不全患者におけるｌｉｋ０６６の使用
CN116036069A (zh) 用于治疗心血管疾病的方法
KR20210038708A (ko) 유데나필 조성물을 이용하여 폰탄 환자에서 심근 성능을 개선시키는 방법
JP2025172745A (ja) 肺動脈性肺高血圧症の治療方法
CA3221343A1 (en) Methods of treating multiple sclerosis
HK40028703A (zh) 用於在肥厚型心肌病的治疗中使用的玛伐凯泰
US20250295639A1 (en) Methods for treating heart diseases
Baig et al. Unleashing an Underlying Serious Cardiac Arrhythmia: A Case of Coronary Vasospasm With Atypical Presentation
In ATHEROSCLEROSIS AND HYPERLIPIDEMIA
Krishnan et al. A Lifetime in the Making
HK40053699A (en) Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject
after Acute Converting Enzyme in Patients
Singh et al. Results: The results by analysis of varience revealed that wall thicknes opposite the site of infarction decreased from (mean±SD) 12.2±2.0 mm to 10.0±1.8 mm with coenzyme Q10 compared with 12.8±2.2 mm to 13.3+ 2.3
WO2017153850A1 (en) Perhexiline dosing regimens for use in the treatment of hypertrophic cardiomyopathy
HK1156502A (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104